Synthetic immunogens for blood stage malaria vaccine against plasmodium falciparum

Applications: Synthetic polypeptides, treatment of malaria, prevention of malaria

Design of synthetic vaccine immunogens which contain the epitopes for the most growth-inhibitory antibodies targeting RH5 and CyRPA: PfRH5-34EM (22015), PfRH5-top (23632), PfCyRPA-BD (23633).

Features	Benefits
Novel, rationally designed synthetic immunogens targeting a specific region of RH5 or CyPRA to which most growth-neutralising antibodies bind.	Overcomes the mixed immune response that is typically elicited when RH5 or CyRPA immunogens are used for vaccination.
Use of structure-guided design to ensure optimised folding of the specified region	Presents the most effective epitope to the immune system
Immunogen series is validated and shown to be efficacious in a pre-clinical rat model	Generates a higher quality antibody response when used for immunisation compared to current vaccines
Could be used by itself, as part of sequence of immunisations with other immunogens or as part of a multi-stage vaccine program	Adaptability in vaccine delivery and program design

Patent pending & available for:

Licensing
Co-development

Request more information
about this technology

Back to Technologies Available

Technologies for License

Synthetic immunogens for blood stage malaria vaccine against plasmodium falciparum

Ready to get in touch?